Radiation oncology expert witness with around 10 years of experience in the management of cancer across all body sites, with clinical focus on genitourinary, gynecologic, skin, and head and neck malignancies, as well as oligometastatic disease. He has 10 years of consulting experience and currently serves as a professor in a department of radiation oncology. His experience includes high-dose rate brachytherapy, low-dose rate brachytherapy, stereotactic body radiation therapy, image-guided radiation therapy, and pencil-beam spot-scanning proton beam therapy. He has also held medical director, attending physician, and clinical program development responsibilities involving external beam radiation, brachytherapy, SBRT, proton therapy, and integrated radiation oncology workflows. He earned an MD and a BA in cell and molecular biology, completed postgraduate training in internal medicine and radiation oncology, and served as chief resident in radiation oncology. He is board certified in radiation oncology through the American Board of Radiology and holds active Medicine and Surgery licensure in Maryland and Pennsylvania. His professional involvement includes the American College of Radiology, American College of Radiation Oncology, American Brachytherapy Society, and American Society for Radiation Oncology. He has also contributed to quality and safety review work, departmental practice guidelines in bladder cancer, skin cancer, and prostate cancer, SBRT working group activity, and editorial work in radiation oncology. His clinical practice includes image-guided brachytherapy for cervical cancer, skin surface brachytherapy for skin cancer, HDR brachytherapy with MRI planning for prostate cancer, and identification and treatment planning for patients who may benefit from proton therapy. He has participated in treatment planning rounds, case presentations, resident and fellow education, and community radiation oncology rounds. His clinical and research activity includes prostate brachytherapy, stereotactic body radiation therapy, proton beam radiation, cutaneous malignancies, head and neck cancer, and concurrent radiation and immunotherapy.